Steatohepatitis/Metabolic Liver Disease News

Poxel SA announced initiation of a phase 2a study of PXL770, a direct adenosine monophosphate-activated protein kinase activator for the treatment of non-alcoholic steatohepatitis, according to a company press release.

Many chronic liver complications such as autoimmune hepatitis and nonalcoholic fatty liver disease do not have approved therapies for direct treatment, but the current hepatology pipeline includes several candidates that have recently demonstrated safety in early trials and some that met top-line phase 3 results.

Thirty-three percent of young adults with HIV since birth or early childhood have hepatic steatosis, a prevalence comparable to older adults with HIV and “significantly higher” than HIV-negative controls, according to research published in The Journal of Infectious Diseases

SFA Therapeutics received second patent approval for its liver disease therapy SFA001, according to a press release.

According to a study published in Hepatology, small dense LDL cholesterol independently predicted cardiovascular disease events among liver transplant recipients, according to a study published in Hepatology.

Combined analysis from two large studies verified that the noninvasive tools Fibrosis-4 index, aspartate aminotransferase-to-platelet ratio, and NAFLD fibrosis score were able to detect advanced fibrosis and fibrosis progression in patients with nonalcoholic fatty liver disease.

Measurement of fibroblast growth factor 21, a protein widely expressed in the liver, may predict the severity of nonalcoholic steatohepatitis in adults with obesity or type 2 diabetes, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Diet and lifestyle are tied closely with liver health both as risk factors for complications such as nonalcoholic fatty liver disease and as the best intervention in the case of fatty liver development and progression.

Marshall University and the Joan C. Edwards School of Medicine announced the open recruitment of patients with stage 2 or stage 3 nonalcoholic steatohepatitis for a clinical trial designed to evaluate the safety and efficacy of the investigational drug cenicriviroc for late-stage liver disease, according to a press release.

LPCN 1144 significantly reduced liver fat in patients with nonalcoholic fatty liver disease after 16 weeks, according to a press release from the manufacturer, Lipocine.